Use this link to cite:
https://hdl.handle.net/2183/46105 A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis
Loading...
Identifiers
Publication date
Authors
Juliá, Antonio
Fernández-Nebro, Antonio
Fernández Ortiz, Ana María
Cañete, Juan D.
Maymó, Joan
Alperi-López, Mercedes
Fernández-Gutiérrez, Benjamín
Olivé, Alex
Corominas, Héctor
Advisors
Other responsabilities
Journal Title
Bibliographic citation
Julià A, Fernandez-Nebro A, Blanco F, Ortiz A, Cañete JD, Maymó J, Alperi-López M, Fernández-Gutierrez B, Olivè A, Corominas H, Erra A, Acosta-Colman I, Alonso A, López-Lasanta M, Tortosa R, Tornero J, Marsal S. A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis. Pharmacogenomics J. 2016 Apr;16(2):147-50.
Type of academic work
Academic degree
Abstract
[Abstract] Anti-Tumor Necrosis Factor (anti-TNF) drugs are biologic agents commonly used to treat rheumatoid arthritis (RA). However, anti-TNFs are not effective in approximately one out of four treated patients. We conducted a Genome-Wide Association Study (GWAS) to identify the genetic variation associated with the response to anti-TNF therapy in RA. In the discovery stage, 372 RA patients treated with an anti-TNF agent (infliximab, adalimumab or etanercept) were analyzed and treatment response was defined at 12 weeks of therapy. We found a genome-wide significant association in the MED15 gene with the response to etanercept (P<1.5e-8). Using an independent cohort of 245 RA patients, we performed a replication study of the most significant GWAS associations. We replicated the association at the MED15 locus and found suggestive evidence of association in the previously associated MAFB locus. The results of this study suggest novel mechanisms associated with the response to anti-TNF therapies.